Markets are complacent, but volatility is coming
Markets are coasting on a wave of optimism that looks increasingly untethered from reality, writes Nigel Green.
With the S&P 500, among other indices, brushing against record highs and tech stocks powering ahead, it would be easy to mistake this rally for resilience.
But it's not resilience, it's complacency.
This isn't about fearmongering. It's about realism. While equities flash green, warning signs are piling up fast: renewed trade tensions, stubborn inflation risks, ballooning government debt, and a bond market that's growing less patient by the day.
Add to that the thin trading volumes of the summer months, where small shifts can trigger outsized moves, and we're staring at the likelihood of a sharp uptick in volatility.
Take trade. The US has reignited its protectionist agenda, with fresh tariff threats aimed squarely at China. Talks have stalled, temporary deals remain toothless, tariff levels are still punishing, and supply chains remain under pressure.
With rhetoric on both sides remaining pretty much the same, markets are underestimating the risk of another escalation. Unlike previous episodes, this is not a minor skirmish, it's a deepening economic contest between the world's two largest economies.
Inflation is another pressure point. Investors are betting that price growth will continue cooling, nudging central banks toward rate cuts. That's a risky assumption.
The next round of data could easily surprise to the upside. Labour markets remain tight, and input costs from tariffs and energy are beginning to creep higher. A fresh inflation spike could push rate-cut hopes further into the distance, and valuations would have to adjust accordingly.
Also, the bond market is already signalling discomfort. Treasury yields have been climbing, not because of runaway growth, but because of mounting supply.
The US is issuing record levels of debt to finance deficits that show no sign of narrowing. Overseas buyers, especially China and Japan, are stepping back.
The result is weaker demand, rising yields, and a higher cost of capital rippling across the economy. This isn't the backdrop for a smooth rally in equities.
At the same time, corporate America is flashing its own warning lights. Layoffs are accelerating.
Major firms across tech, finance, and entertainment have all announced significant job cuts in recent weeks. While markets perversely reward these announcements in the short term — interpreting them as margin-boosting measures — the deeper implication is that companies are preparing for slower growth. The earnings optimism driving stocks upward is, in many cases, built on sand.
Yet despite all of this, there's still a strong case for opportunity.
Volatility isn't inherently negative. It's disruptive, yes. But it's also the source of market mispricing, and mispricing is what creates the space for outperformance. When consensus gets lazy, as it has now, bold positioning has room to shine.
That's especially true in this moment. The convergence of rapid technological progress — particularly in AI, automation, and productivity-enhancing innovations — is starting to reshape the profit potential of entire sectors. These forces are disinflationary over the medium term, even as short-term price pressures remain stubborn.
The companies that harness them early will not just weather volatility, they'll emerge stronger.
The key is not to flee risk, but to understand it and position intelligently. Passive portfolios anchored to a backward-looking view of the economy are vulnerable.
Diversification across geographies, sectors, and asset classes, will matter more than ever. So will exposure to forward-facing megatrends, from clean energy to semiconductors to AI infrastructure.
This summer, markets won't drift quietly. With liquidity thinner, every data release and policy signal will carry more weight.
Sudden swings are not just possible but likely. But that's precisely what makes this period one of the most promising entry points in recent memory. Those who wait for perfect clarity will miss the window.
The exuberance in today's equity markets is not sustainable. It's built on the hope of soft landings, timely rate cuts, and diplomatic breakthroughs.
But hope isn't a strategy. The coming months will test the market's assumptions and many won't hold. Yet that doesn't mean retreat is the right move, it means preparation is key.
Investors willing to engage with this volatility, not hide from it, are far more likely to capture the upside when it comes.
Nigel Green, is the group CEO and founder of deVere Group, an independent global financial consultancy.
The views, information, or opinions expressed in the interviews in this article are solely those of the author and do not represent the views of Stockhead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
34 minutes ago
- News.com.au
Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers Among other auspicious events, the 19th of June marks the end of slavery in the US, Garfield the Cat Day and the birthdays of former British PM Boris Johnson and royal temptress Wallis Simpson. So why not add a slew of meaningful life sciences announcements, including an HIV vaccine breakthrough, to the June 19 pantheon? Let's start with Orthocell (ASX:OCC), which reports 'compelling data' showing its Remplir nerve repair agent is superior to suture-only standard techniques. Stitching accounts for circa 90% of the 700,000 nerve repair procedures done in the US annually. A cuff that envelops the damaged peripheral nerves, Remplir reduces the use of stitching, which can compromise nerve repair. Orthocell's study used a rat sciatic nerve injury model, covering 48 rodents across four treatment groups. These cohorts covered repairs using one, three or six sutures, compared with one suture augmented with Remplir. The rats' nerve function and regeneration were evaluated up to 12 weeks post-treatment. The FDA ticked off Remplir in early April and the device is also approved in Canada, Hong Kong, Singapore, New Zealand and here. Thus, the study was pitched not so much as approval as supporting the US sales rollout. Orthocell cites a total addressable market in its target markets of US$3.5 billion, with its already-approved geographies accounting for US$1.8 billion. The US market is worth US$1.6 billion. Stem-cell hope for bone marrow transplant patients NeuroScientific Biopharmaceuticals (ASX:NSB) highlights previous clinical data showing its soon-to-be acquired stem cell platform is effective in preventing graft-versus-host disease (GvHD). The company is buying the asset, Stemsmart from the unlisted Perth-based Isopogen. The phase I work covered adults and children with life-threatening, steroid-resistant GvHD, a common complication of bone-marrow transplants. The data shows the treatment is safe and well tolerated, 'with no infusion related toxicities'. Furthermore, most adults and children had a 'complete or partial resolution of symptoms and improved survival'. Of the 10 children treated on compassionate grounds, all had survived 12 months post implant. Three of them were still alive six years post treatment. Turning to pancreatic cancer, Amplia (ASX:ATX) reports another patient with a 'complete response' in its 55-patient trial dubbed Accent. As close as dammit to a cure, a confirmed complete response formally is defined as all tumour lesions disappearing, with the effect maintained for at least two months. 'This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body,' the company says. A Singularly fine US deal Imaging medtech outfit Singular Health Group Ltd (ASX:SHG) has signed a $2 million agreement with a US physician network to develop and use Singular's 3Dicom medical imaging tool. The compact is with Provider Network Solutions (PNS), covering physician networks in Puerto Rico, Florida, and Texas. It covers the initial deployment of 1000 3Dicom licences, at US$800 each. Singular pockets a further US$500,000 on 'satisfaction of AI model marketplace and image repository development and integration'. The company hope to expand to the remaining 30 states that PNS covers. 3Dicom converts magnetic resonance imaging and computed tomography scans to enable 'immersive visualisation' with three-dimensional images. Singular also said it had received $8 million of firm commitments in its recently-announced placement. Meanwhile, microbiome testing house Microba Life Sciences (ASX:MAP) is on trading halt pending a capital raising. EZZ girds for US launch Hitherto China and locally focused, health supplements outfit EZZ Life Science (ASX:EZZ) has launched four initial products into the US after winning FDA approval. To be sold under the new Ezzday banner, the products are made in the US and are tailor-made for American consumers. Seeing you asked, the remedies cover de-bloating/de-gassing, vaginal probiotics, skincare and colon detox. Readers can draw their own conclusions as to what that means about the State of the Nation in Trumpian times. Initially, the products will be sold via Amazon and Shopify. Locally EZZ sells via more than 600 chemists and globally via 750 ecommerce platforms, including China's Douyin and Tmall. The company values the US supplements market at US$100 billion a year, pipping China's US$80 billion opportunity. US health secretary Robert F Kennedy Junior (RFK Jr) has a special interest in health supplements, which at the very least shouldn't harm EZZ's US ambitions. EZZ shares have been on a tear – up 33% over the last month – but they are still well shy of the record $5 peak in October last year. HIV jab spells hope for end to '45-year pandemic' Speaking of RFK Jr, the FDA has approved a drug that is meant to protect against HIV with a single administration every six months. Yep – it's a vaccine – so maybe the health czar isn't as avowedly anti-vaxx as we all think. Marketed as Yeztugo by Gilead Sciences, lenacapavir is seen as the best hope of knocking HIV – in effect a 45-year pandemic – on its head. Clinicians say the drug is much more powerful than the current oral treatments and almost 100% effective. 'This is a historic day in the decades-long fight against HIV,' Gilead CEO Daniel O'Day said. 'Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.' The drug has a list price of US$28,218 ($43,300). But Gilead may provide the vaccine free to non-insured patients. Have investors underestimated Clarity? Is radiopharmacy outfit Clarity Pharmaceuticals (ASX:CU6) a case of 'objects in this rear view mirror are closer than you think'? Following a series of clinical updates from Clarity, broker Canaccord values the company at $6.74 a share, a lofty 210% increment on the current price. In March, Wilsons ascribed an even ballsier $8.25 a share. All things being equal – and they never are – that would value Clarity at $2.6 billion. Sector champ Telix Pharmaceuticals (ASX:TLX) is worth around $8 billion, bearing in mind it has two FDA-approved prostate cancer imaging tools and a kidney cancer consent in the offing. Yesterday, Clarity said it has struck an agreement with US mob Spectronrx. Spectronrx will provide 400,000 patient-ready does of its copper isotope based 64Cu-SAR-bisPSMA (for diagnosing and potentially treating prostate cancer). In the nuclear medicine game, gaining access to nearby doses is half the battle. But this agent's generous half-life means it can be distributed across all 50 US states. Clarity recently announced promising phase II results for 64Cu-Sartate (neuroblastoma) and 64Cu-SAR-Bombesin (PSMA-negative prostate cancer). Another program, Secure, focuses on identifying and treating metastatic castration-resistant prostate cancer. Clarity currently has no approved products, but Canaccord expects 64Cu-SAR-bisPSMA to be on market by mid 2027. 'Recent commercial agreements should remind the market that this potential best-in-class asset could be closer than we think.' The firm reckons Clarity can win a 20% share of the US market, for US$520m in peak sales. Your columnist's nuclear science credentials – the ones plucked from a Weeties pack – are out of date. But it looks like Telix should have one eye on the rear-view mirror and the other on the road ahead.
Perth Now
an hour ago
- Perth Now
Banks snap losing streak but market remains weak
Australia's share market is edging lower as investors await the next development in the Middle East conflict, but local banks are making a comeback after six weak sessions. The S&P/ASX200 is down 18.3 points, or 0.21 per cent, to 8,511.7, as the broader All Ordinaries fell 24.4 points, or 0.28 per cent, to 8,733.5. The weak start came after a similar session on Wall Street overnight, as White House officials mulled a potential attack on Iran and after the US Federal Reserve conceded stagflation risks were rising in the world's largest economy. Market participants remained edgy and uncertain about the Middle East conflict and potential US military involvement, market analyst Kyle Rodda said. "Such a scenario would raise the risk of a greater regional conflict, with implications for global energy supply and, probably, economic growth." Despite seven local sectors trading lower by lunchtime, financials staged a comeback with a 0.5 per cent gain after fading 1.5 per cent in the previous six sessions. Westpac was leading the charge, up 1.5 per cent to $33.50, while NAB and CBA pushed 0.7 per cent and 0.5 per cent higher respectively. The NAB rise came despite the Australian Competition and Consumer Commission fining the bank $750,000 over breaches to Consumer Data Right rules. Materials was the worst-performing sector with a 1.5 per cent slip, as weak iron ore prices continued to weigh on large caps BHP (-1.5 per cent), Rio Tinto (-1.7 per cent) and Fortescue (-1.3 per cent). Gold miners also traded lower as the safe haven's price continued to coil in a slight downward trajectory, with futures trading at $US3,396 ($A5,232) an ounce. Energy stocks fell 0.6 per cent, as oil and gas giants Woodside (-0.6 per cent) and Santos (-0.3 per cent), handed back some earlier gains as oil prices consolidated after their recent run-up. Futures in global benchmark Brent Crude were trading at $US74.74 a barrel, roughly on par with yesterday's ASX close. Australia's tech sector was down 0.9 per cent after hitting an intraday record on Wednesday, with WiseTech Global weighing heavily with a 1.6 per cent slip to $107.15 after announcing the departure of two board members. Directors Charles Gibbon and Michael Gregg had been long-time supporters of founder and executive chair Richard White, who has been at the centre of a number of scandals at the company. Utilities continued to sell off after Friday's 4.2 per cent surge. The sector has lost 3.5 per cent in value in the subsequent four sessions. The Australian dollar is buying 64.84 US cents, down from 65.07 on Wednesday at 5pm, and edging lower after Australia's unemployment rate held steady in May, offering no surprises in economic data ahead of a widely expected Reserve Bank rate cut in July.
News.com.au
an hour ago
- News.com.au
Auction of Pope Leo XIV's childhood Chicago home extended
The highly-publicised auction of Pope Leo XIV's childhood home has been extended by a month — after it was revealed the Chicago suburb where he was raised was launching a bid to acquire the humble dwelling so it can be preserved as a local landmark. Pope Leo, who was born Robert Francis Prevost, spent several years living in a small three-bedroom, three-bathroom dwelling in Dolton, Illinois. His father, Louis Prevost, sold the property in 1996, according to records, after which it was sold on two other occasions. According to Realtor, the current owner, property flipper Pawel Radzik, acquired the three-bedroom, three-bathroom abode in March 2024 for $US66,000 ($A101,553) and had initially planned to renovate it, then sell it off — until that is, one of its former residents was chosen to succeed the late Pope Francis during the conclave in May. At the time, the property was on the market for just $US199,900 ($A307,605); however, it was swiftly delisted just hours after Pope Leo's new historical role was revealed. It was later revealed the home was being put up for auction via Paramount Realty USA — with listing agent Steve Budzik noting the decision to sell the property to the highest bidder came after his team struggled to settle on an appropriate listing price for an abode with such historical significance. However, the home's journey took another twist when the Village of Dolton, with support from the Chicago Archdiocese, announced plans to acquire the house, either by buying it, or by using eminent domain to take over ownership. 'The Village of Dolton intends to purchase this home either through direct purchase or through their eminent domain power,' Odelson wrote in a letter sent to Paramount Realty USA, according to the New York Times. 'The Village intends to work with the Chicago Archdiocese and other agencies to allow the home to be viewed and visited by the public as a historic site.' Odelson added discussions with the seller were underway, saying the Village of Dolton and the local archdiocese would prefer not to rely on eminent domain for the acquisition of the home because it would garner too much media attention. '[It] keeps the home in the news and not the light that the village or the church want,' he said. 'We don't want it to be a controversy; we want it to be a sacred site.' Initially, the auction of the property was due to close on June 18. However, an update to the listing has now extended the bidding process to July 17, with Budzik explaining to via email this was done in order to 'allow more time for bidders to review, perform due diligence, and bid'. A spokesperson for Paramount Realty USA added the extended auction window will also give bidders an opportunity to 'tour the property' if they wish. Neither Budzik nor Paramount Realty USA commented on whether negotiations with the Village of Dolton had any bearing on the decision to extend the auction. After Dolton announced its plans to acquire the home, Budzik told his client was very much open to working with its representatives, as well as the Chicago Archdiocese, stating in an email: 'The seller is open to the potential opportunity of working with the Village of Dolton to purchase the property at fair market value. 'We also understand that the Chicago Archdiocese could be involved in making this a historical landmark, which is great news for the seller. We would love to come to a mutually beneficial agreement in the coming days.' To make matters more complicated, CBS News reported on June 16 a motion had been filed seeking a preliminary injunction to block the Village of Dolton from using taxpayer money in order to buy Pope Leo's childhood home. This motion is understood to have been filed as part of an ongoing wrongful termination lawsuit filed against Dolton by a former employee, Lavell Redmond, who claimed in a 2022 filing that his employers had refused to discuss terms of a settlement because the village did not have sufficient funds. In his June 15 motion, Redmond's lawyers claimed Dolton is in 'severe financial distress' and made several allegations of financial mismanagement, unresolved legal obligations, and a potential misuse of taxpayer funds. Matthew R. Custardo, the lawyer who filed the motion, stated to WGN9 the injunction was being sought in order to stop 'hypocrisy,' insisting the injunction would in no way hinder the sale of the home but rather prevent local politicians from using taxpayer funds in order to take it over. 'This isn't about stopping history. It's about stopping hypocrisy,' he said. 'You can't cry broke in court and then try to spend taxpayer funds on non-essential acquisitions.' While bids for the property start at $US250,000 ($A385,148), it is widely predicted the home could sell for much more, although experts have hesitated to put a specific value on the property in the weeks since the auction was announced. The online auction house also provides a copy of the original purchase deed from the 1949 sale of the home to Pope Leo's father, Louis, which is dated March 3 of that year.
